Aim: To compare the anti-inflammatory effects of Metformin sulfonylurea and
Sitagliptin combination with Metformin Sulfonylurea and Acarbose combination
in Type2DM patients by using Anti-inflammatory markers (IL6, hs CRP) and also
To compare the clinical outcome between these two groups by using the following
parameters FBS, PPBs, HbA1C, Plasma Insulin.
Materials and Method : In this study 30 type 2 diabetes patients on Metformin
and Sulfonylurea combination ,HbA1c value >7.5 were recruited and randomized
into two groups in which one group was added on Acarbose and the other group
was added with Sitagliptin along with Metformin, Sulfonylurea combinations and
followed for 3 months.
Result :
In this study Sitagliptin combination reduced the mean value of FBS, PPBS,
HbA1c, Plasma Insulin , Insulin Resistance ,hsCRP and IL-6 , which were similar
to the results of previous studies. In Acarbose combination, there was a reduction
in the mean values of FBS,PPBS, HbA1c, Plasma Insulin, Insulin Resistance,
hsCRP but not IL-6. Hence long term follow up and large sample size may be
required to see the progression in the reduction of inflammatory markers and the
role of these drugs in the insulin resistant states.
Conclusion : This study explained the synergism when Sitagliptin given along
with Metformin Sulfonylurea combination and has proved a definite role in
reducing chronic inflammation
